Cardiokol

Voice-based Markers for Large-scale Monitoring and Screening of Heart Rhythm Disorders

Health Tech & Life Sciences
Active
Seed " Founded 2017
Total raised
$8.0M
Last: Seed 2019-09
Stage
Seed
Founded
2017
Headcount
9
HQ
"
Sector
Health Tech & Life Sciences

About

Cardiokol is a privately owned digital telehealth company that develops voice-based markers and methods for monitoring and screening heart rhythm disorders in large at-risk populations. The company utilizes proprietary technology that is implemented in speech platforms such as landlines, smart phones, smart speakers, and voice assistants. Cardiokol offers low-cost, long-term, and user-friendly monitoring solutions, applicable for monitoring at-risk populations of older adults (65+).

Funding history · 1 round · $8.0M total

2019-09
Seed $8.0M

Company Intelligence Q&A

Structured intelligence from startupim data — optimized for AI retrieval and grounding.

What is Cardiokol's primary focus?
Cardiokol is a digital telehealth company that develops voice-based markers and methods for monitoring and screening heart rhythm disorders in large at-risk populations.
When was Cardiokol founded?
Cardiokol was founded in August 2017.
How much funding has Cardiokol raised in total?
Cardiokol has raised a total of $8,000,000 USD.
Which investors participated in Cardiokol's Seed round?
In September 2019, Cardiokol's Seed round included lead investor Kamet Ventures, and also KYTO.
What is the approximate employee count for Cardiokol?
Cardiokol has 9 employees.
What are the primary geographic markets for Cardiokol?
Cardiokol's primary geographic markets are the United States and Europe.
What type of technology does Cardiokol utilize?
Cardiokol utilizes proprietary technology implemented in speech platforms, including Artificial Intelligence, Machine Learning, Voice & Speech Recognition, Semiconductors & Electronics, and Digital Signal Processor.
Has Cardiokol received any grants?
Cardiokol has received a grant from the IIA.
What was a notable partnership for Cardiokol in late 2021?
In November 2021, Cardiokol joined Bayer's G4A program, as reported by MobiHealthNews.

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesDigital HealthcarePatient Remote Monitoring
Technologies
Artificial IntelligenceMachine LearningVoice & Speech RecognitionSemiconductors & ElectronicsDigital Signal Processor
Target customers
ConsumersDemographics & FamilySeniorsHealthcare & Life SciencesHealthcareProviders
Business model
B2B

Highlights

1 PatentsVerified

Tags

deep-neural-networksdisease-management5g-networkssignal-processingmachine-learningstrokeseniorsbiomarkersheart-diseasesdata-analyticsartificial-intelligencedigital-healthcareheart-failurevoice-analyticscardiologypreventionremote-monitoringtelehealth